There are nearly 200,000 cases of prostate cancer every year. The most common treatment for prostate cancer is surgery in the early stages. Other treatments include chemotherapy, radiation therapy, and palliative care to alleviate symptoms. For patients in advanced stages or are ineligible for surgery, clinical trials provide early access to treatment options before they are widely available or used as standard of care. Some of the treatments used are targeted for specific genetic mutations and subtypes of prostate cancer, which may be more beneficial for patients than standard treatment options. Every patient is different, so it is important to speak with your doctor about the possibility of enrolling in a prostate cancer clinical trial.
There are over 900 clinical trials recruiting prostate cancer patients. Going through each one is time consuming, even though patients are only eligible for a select list of trials. Artificial-Intelligence tools can quickly match prostate cancer patients to clinical trials based on their preferences, location, and medical history. The Clinical Trial Matching System (CTMS) from Massive Bio provides personalized matches for patients of all cancer types, including prostate cancer. The CTMS eliminates the time sorting through trials by pre-screening the prostate cancer patient for each trial to identify which ones they will be eligible for.